Adding PARP inhibitors to maintenance therapy was shown to prolong progression-free survival in patients with advanced ovarian cancer.
European Society for Medical Oncology Gynaecological Cancers Congress
Maintenance therapy with niraparib may improve survival in patients with ovarian cancer.
Advertisement
The results of the first therapy to use a PARP inhibitor with chemotherapy for patients with ovarian cancer were presented at ESMO Congress 2019.
A new study looked at trametinib's effect on survival and response rates in ovarian cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
Daratumumab Approval May Be “Game Changer” in High-Risk Smoldering Myeloma
3
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
4
Palazestrant Combo Shows Preliminary Activity in ER+/HER2– Breast Cancer
5
